Abstract
The antiepileptic drug, vigabatrin, inhibits GABA transaminase, thus elevating GABA levels in the brain. In adult animal experiments, high-dose (200 mg/kg/day) chronic vigabatrin administration is associated with potentially reversible myelin vacuolation, a phenomenon not documented in humans. We hypothesized that vigabatrin might adversely affect myelination in the developing brain. Rats were given vigabatrin in doses comparable to those used clinically (15-50 mg/kg/day), from age 12 to 16 days. The rats were killed at age 19-20 days. We observed decreased myelin staining in the external capsule, axonal degeneration in white matter, evidence of glial cell death in the white matter, and reactive astrogliosis in the frontal cortex. We did not detect myelin vacuolation. These findings indicate that vigabatrin can have adverse and potentially irreversible effects on the developing rat brain. The mechanism of damage could be direct toxicity of vigabatrin or an indirect effect mediated through elevated GABA levels. Vigabatrin has been recommended as a treatment for some forms of childhood epilepsy; therefore, further studies are needed to assess the risks in children.
References
Jan 1, 1990·Developmental Neuroscience·S M LeVineW B Macklin
Jan 1, 1991·Journal of Child Neurology·D J CannonP J Lewis
Jan 1, 1990·Toxicologic Pathology·J P GibsonJ W Newberne
Sep 1, 1989·The Journal of Physiology·Y Ben-AriJ L Gaiarsa
Jan 1, 1989·British Journal of Clinical Pharmacology·J J HauwC Duyckaerts
Jan 1, 1989·British Journal of Clinical Pharmacology·L I PerssonM Nilsson
Jan 1, 1989·Epilepsia·W H Butler
Jan 1, 1989·Epilepsia·P J RiekkinenT Halonen
Jun 1, 1989·Canadian Journal of Physiology and Pharmacology·S Liske, M E Morris
Apr 1, 1988·Journal of Neurocytology·M B Graeber, G W Kreutzberg
May 1, 1987·Journal of Neuropathology and Experimental Neurology·B A BrodyF H Gilles
Jan 1, 1985·Journal of Neurochemistry·F VaccarinoE Costa
Sep 21, 1984·Science·W M CowanB B Stanfield
Oct 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·A GuidottiE Costa
Oct 1, 1994·Neurology·K L WeissJ C Arezzo
May 1, 1994·Epilepsy Research·G D JacksonJ S Duncan
Sep 1, 1993·Toxicologic Pathology·J T YarringtonR J Marler
Mar 19, 1993·Brain Research. Developmental Brain Research·J Y LimJ D Kocsis
Jan 1, 1993·Neuroscience and Biobehavioral Reviews·P J MorganeJ R Galler
Oct 1, 1995·Neuropediatrics·P UldallH Høgenhaven
Jan 1, 1995·Pharmacology & Therapeutics·R E Appleton
Jul 1, 1996·Epilepsia·J AicardiS Wood
May 1, 1996·Neurochemistry International·E Y ChoiS Y Choi
Feb 2, 1996·Neuroscience Letters·A ShuaibT Wishart
Aug 1, 1963·The Journal of Comparative Neurology·S JACOBSON
Citations
Jun 7, 2000·Epilepsia·M QiaoU I Tuor
Sep 30, 2016·Psychopharmacology·Karen SousaJaqueline Nascimento Picada
Sep 24, 2009·Journal of Child Neurology·Myles HortonMarc R Del Bigio
Oct 27, 2015·Human & Experimental Toxicology·V R CoelhoP Pereira
Aug 31, 2010·AJNR. American Journal of Neuroradiology·G N SimaoE Widjaja
Mar 26, 2005·Current Opinion in Neurology·Raili Riikonen
Jun 23, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·S J Spence, R Sankar
Feb 24, 2001·Epilepsia·A N PrasadD J Buckley
May 23, 2000·Journal of Neurochemistry·K Lukasiuk, A Pitkänen
Oct 20, 2006·Neuroscience·R Káradóttir, D Attwell
Oct 9, 2021·Toxicologic Pathology·Brad BolonRobert H Garman